The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Deshkina T.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Kornietskaia A.L.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Toxicity and efficacy of panitumumab in metastatic colorectal cancer

Authors:

Deshkina T.I., Kornietskaia A.L., Bolotina L.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2013;2(6): 51‑55

Read: 8341 times

Download PDF (RU)
Contact the author
Table of contents

TOXICITY AND EFFICACY OF PANITUMUMAB IN METASTATIC COLORECTAL CANCER
TOXICITY AND EFFICACY OF PANITUMUMAB IN METASTATIC COLORECTAL CANCER

To cite this article:

Deshkina TI, Kornietskaia AL, Bolotina LV. Toxicity and efficacy of panitumumab in metastatic colorectal cancer. P.A. Herzen Journal of Oncology. 2013;2(6):51‑55. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Prognostic factors for the effe­ctiveness of transarterial chemoembolization in patients with seco­ndary liver tumors. P.A. Herzen Journal of Onco­logy. 2026;(1):5-10
Comparative analysis of longitudinal and transverse mini­laparotomy during colon cancer surgery. Piro­gov Russian Journal of Surgery. 2025;(4):71-78
Ergo­spirometry for preoperative risk asse­ssment in patients with colo­rectal cancer. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):70-77
Inte­rleukin-6 as a biochemical marker of inte­stinal anastomotic leakage. Piro­gov Russian Journal of Surgery. 2025;(9):87-93
Anomaly of infe­rior mese­nteric vein anatomy in a patient with sigmoid colon cancer. Piro­gov Russian Journal of Surgery. 2025;(12):151-155
Transanal endo­scopic and robot-assisted microsurgery for rectal tumors. Piro­gov Russian Journal of Surgery. 2026;(1):26-32
Hete­rogeneity of mismatch repair protein expression in tumors. Russian Journal of Archive of Pathology. 2026;(1):73-79
Ibuprofen combined with low-molecular-weight hepa­rin does not affect hemo­stasis system in patients unde­rgoing colo­rectal cancer surgery. Russian Journal of Anesthesiology and Reanimatology. 2026;(1):52-56
Abstract:

The paper describes two clinical cases of using the targeted drug panitumumab in patients with metastatic colorectal cancer. It evaluates the direct efficiency of this treatment option and its related skin toxicity.

Keywords:

colorectal cancer
panitumumab
skin toxicity

Authors:

Deshkina T.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Kornietskaia A.L.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Close metadata

References:

  1. Chissov V.I., Starinskii V.V., Petrova G.V., red. "Zlokachestvennye novoobrazovaniya v Rossii v 2010 godu. M.; 2012: 4-5.
  2. Boyadzis M., Lebouits P., Freim Dzh. Kratkoe rukovodstvo po lecheniyu opukholevykh zabolevanii. M.; 2009: 86.
  3. Chissov V.I., Davydov M.I., Frank G.A., Dar'yalova S.L. Onkologiya. Natsional'noe rukovodstvo. M.; 2008: 705.
  4. Abdalla E.K., Vauthey J.-N., Ellis L.M. et al. Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection. Ablation for Colorectal Liver Metastases. Ann. Surg. 2004; 239: 818-27.
  5. Aloia T.A., Vauthey J.-N., Loyer E.M. et al. Resection of colorectal liver metastases. Arch. Surg. 2006; 141: 460-7.
  6. Bolton J.S., Fuhrman G.M. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann. Surg. 2000; 231: 743-51.
  7. Ekberg H., Tranberg K.G., Andersson R. et al. Determinants of survival in liver resection for colorectal secondaries. Br. J. Surg. 1986; 73: 727-31.
  8. De Gramont A., Figer A., Seymour M. et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000; 18: 2938-47.
  9. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P. et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000; 355: 1041-7.
  10. Goldberg R.M., Sargent D.J., Morton R.F. et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22: 23-30.
  11. Scheithauer W., Rosen H., Kornek G.V. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993; 306: 752-5.
  12. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S. et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26 (10): 1626-34.
  13. Peeters M., Van Cutsem E., Siena S., Humblet Y., Alain Hendlisz A. et al. A Phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs. BSC alone in patients with metastatic colorectal cancer. Proc. Am. Assoc. Cancer Res. 2006; 47: A CP-1, abstr.
  14. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 2010; 28 (31): 4706-13.
  15. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R. et al. Randomized phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 2010; 28 (31): 4697-705.
  16. Artamonova E.V. Panitumumab v terapii metastaticheskogo kolorektal'nogo raka: dannye klinicheskikh issledovanii, problema kozhnoi toksichnosti. Sovremennaya onkologiya. 2010; 12 (3).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.